Payment overview · 2025
General Payments
$28.70
2 reported records · 2 companies
Healthcare provider profile · identity verified
William Daniel King, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EUFAULA, AL · NPI 1891715892
Verified facts
What the public records show
CMS Open Payments records show William Daniel King, MD received $28.70 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 50.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.58 | 50.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.12 | 49.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $28.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
238 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 804 | 211 |
| Atorvastatin Calcium | Atorvastatin Calcium | 632 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 590 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 521 | 118 |
| Omeprazole | Omeprazole | 487 | 133 |
| Hydrochlorothiazide | Hydrochlorothiazide | 429 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 425 | 111 |
| Metformin Hcl | Metformin Hcl | 406 | 110 |
| Zolpidem Tartrate | Zolpidem Tartrate | 357 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 355 | 100 |
| Potassium Chloride | Potassium Chloride | 342 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 319 | 133 |
| Duloxetine Hcl | Duloxetine Hcl | 302 | 68 |
| Montelukast Sodium | Montelukast Sodium | 282 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 84 |
| Simvastatin | Simvastatin | 278 | 77 |
| Buspirone Hcl | Buspirone Hcl | 275 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 242 | 62 |
| Eliquis | Apixaban | 238 | 38 |
| Lisinopril | Lisinopril | 232 | 60 |
| Gabapentin | Gabapentin | 221 | 61 |
| Telmisartan | Telmisartan | 220 | 50 |
| Januvia | Sitagliptin Phosphate | 208 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 82 |
| Trazodone Hcl | Trazodone Hcl | 189 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 172 | 45 |
| Celecoxib | Celecoxib | 171 | 50 |
| Allopurinol | Allopurinol | 170 | 45 |
| Furosemide | Furosemide | 166 | 51 |
| Tramadol Hcl | Tramadol Hcl | 161 | 38 |
| Metformin Hcl Er | Metformin Hcl | 157 | 46 |
| Carvedilol | Carvedilol | 153 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 45 |
| Naproxen | Naproxen | 138 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 32 |
| Jardiance | Empagliflozin | 109 | 23 |
| Meloxicam | Meloxicam | 108 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 26 |
| Farxiga | Dapagliflozin Propanediol | 97 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 70 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 22 |
| Mounjaro | Tirzepatide | 88 | 18 |
| Pregabalin | Pregabalin | 86 | 26 |
| Sertraline Hcl | Sertraline Hcl | 84 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 27 |
| Atenolol | Atenolol | 77 | 19 |
| Ozempic | Semaglutide | 72 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 18 |
| Ezetimibe | Ezetimibe | 63 | 15 |
| Meclizine Hcl | Meclizine Hcl | 62 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 18 |
| Finasteride | Finasteride | 60 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 11 |
| Prednisone | Prednisone | 57 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 13 |
| Clonidine Hcl | Clonidine Hcl | 55 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 13 |
| Azelastine Hcl | Azelastine Hcl | 52 | 30 |
| Raloxifene Hcl | Raloxifene Hcl | 52 | 14 |
| Temazepam | Temazepam | 51 | suppressed |
| Entresto | Sacubitril/Valsartan | 50 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 50 | 14 |
| Donepezil Hcl | Donepezil Hcl | 49 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 16 |
| Bumetanide | Bumetanide | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | 13 |
| Nifedipine Er | Nifedipine | 45 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 14 |
| Famotidine | Famotidine | 44 | 13 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 26 |
| Nitroglycerin | Nitroglycerin | 40 | 28 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Famciclovir | Famciclovir | 38 | 16 |
| Fluocinonide | Fluocinonide | 38 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 26 |
| Primidone | Primidone | 35 | 15 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 11 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 24 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Colchicine | Colchicine | 23 | 13 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $28.70 · 2 records | PFIZER INC. | MOUNJARO, NURTEC ODT, PAXLOVID | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error